Therapy Using Stem Cells, Bone Marrow Cells, Appears Safe for Patients With Ischemic Cardiomyopathy

An unresolved issue to whether mesenchymal stem cells have similar safety and possibly greater value than bone marrow mononuclear cells which would be an effective proregenerative treatment for ischemic cardiomyopathy.   65 patients were included in the study that had ischemic cardiomyopathy.  Each patient was injected with mesenchymal stem cells (n=19) with placebo (n = 11) and bone marrow mononuclear cells (n = 19) with placebo (n = 10) with 1 yr. follow up.  The primary measured outcome was treatment emergent 30 day serious adverse event rate that which is defined as composite of death, heart attack, stroke, hospitalization for worsening heart failure, perforation (rupture), tamponade (compression of the heart due to collection of blood or fluid), or sustained ventricular arrhythmias.  No patient had treatment emergent-serious adverse event at day 30.  Over 1 yr. the score improved with mesenchymal stem cells and with bone marrow cells but not with placebo, additionally the 6-minute walk distance increased with mesenchymal stem cells only.

 

http://www.sciencedaily.com/releases/2013/11/131118102626.htm

http://media.jamanetwork.com/news-item/therapy-using-stem-cells-bone-marrow-cells-appears-safe-patients-ischemic-cardiomyopathy/